STOCK TITAN

Henry Schein cuts 2026 non-GAAP EPS view to $5.42–$5.48

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Henry Schein, Inc. (HSIC) will, beginning with its fourth-quarter 2026 results, exclude from non-GAAP results gains from remeasuring previously held equity interests to fair value when it obtains control of a business. Management says the change better reflects underlying operating performance and improves comparability; it does not affect the company’s reported GAAP results. Historical non-GAAP diluted EPS, segment operating income and Adjusted EBITDA for 2024, 2025 and the first nine months of 2026 were recast.

Henry Schein updated FY2026 non-GAAP diluted EPS guidance to $5.42 to $5.48 from $5.50 to $5.56, a stated $0.08 reduction reflecting gains excluded that were recognized in the first quarter of 2026. The company said there are no other changes to 2026 guidance or its underlying business outlook; total sales growth remains 4.5% to 5.5%, and Adjusted EBITDA growth remains high-single-digits. It intends to apply this treatment to acquisition-related remeasurement gains going forward.

The company said it cannot reconcile 2026 non-GAAP EPS and Adjusted EBITDA guidance to projected GAAP measures without unreasonable effort, citing difficulty estimating restructuring and related costs and their tax effects. It said the unavailable information could be material to future results.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FY2026 non-GAAP diluted EPS guidance $5.42 to $5.48 Updated guidance
FY2026 non-GAAP diluted EPS guidance $5.50 to $5.56 Previous guidance
Guidance reduction $0.08 per diluted share Reflects exclusion of remeasurement gains recognized in the first quarter of 2026
Total sales growth guidance 4.5% to 5.5% FY2026; unchanged
Recast non-GAAP diluted EPS $4.58 per diluted share Full year 2024
Recast non-GAAP diluted EPS $4.65 per diluted share Full year 2025
Recast non-GAAP diluted EPS $4.06 per diluted share First nine months of 2026
non-GAAP financial measures financial
"presentation of certain non-GAAP financial measures"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
fair value financial
"remeasurement to fair value of previously held equity interests"
Fair value is an estimate of what an asset or company is really worth today, derived from expected future earnings, comparable market prices and other relevant facts—like agreeing a price for a used car after checking mileage, condition and similar listings. Investors use fair value to decide whether a stock looks overpriced or undervalued, which helps guide buy, hold or sell decisions and sets expectations for potential returns and risk.
non-controlling equity interest financial
"previously held a non-controlling equity interest"
Adjusted EBITDA financial
"2026 Adjusted EBITDA guidance"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
diluted EPS financial
"FY2026 non-GAAP diluted EPS guidance"
Diluted earnings per share (EPS) shows how much profit a company makes for each share of stock, assuming all possible shares from stock options or convertible securities are used. It provides a more conservative estimate than basic EPS, accounting for potential share increases that could dilute ownership. Investors use diluted EPS to get a clearer picture of a company's true profitability on a per-share basis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is HSIC's updated FY2026 non-GAAP diluted EPS guidance?

Henry Schein's updated FY2026 non-GAAP diluted EPS guidance is $5.42 to $5.48, compared with previous guidance of $5.50 to $5.56. The company stated that the $0.08 reduction reflects the exclusion of acquisition-related remeasurement gains recognized in the first quarter of 2026.

Why did Henry Schein change its non-GAAP EPS presentation?

Henry Schein will exclude acquisition-related remeasurement gains from non-GAAP results beginning with its fourth-quarter 2026 results. The gains arise when the company obtains a controlling interest in a business in which it previously held a non-controlling equity interest.

Did HSIC change its 2026 sales and Adjusted EBITDA growth guidance?

No. Henry Schein said total sales growth guidance remains 4.5% to 5.5% and Adjusted EBITDA growth guidance remains high-single-digits, with no other changes to its 2026 financial guidance or underlying business outlook as a result of the presentation change.

What were Henry Schein's recast non-GAAP diluted EPS figures?

The recast non-GAAP diluted EPS figures were $4.58 for 2024, $4.65 for 2025 and $4.06 for the first nine months of 2026. The company provided the recast historical figures to facilitate comparisons across periods.

Why didn't Henry Schein reconcile its 2026 non-GAAP guidance to GAAP?

The company said it could not provide the reconciliation without unreasonable effort because it could not estimate restructuring and related costs, including costs for ongoing value-creation initiatives, and the corresponding tax effect. It said the unavailable information could be material to future results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001000228 false NASDAQ 0001000228 2026-11-16 2026-11-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 16, 2026
Henry Schein, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
0-27078
(Commission
File Number)
11-3136595
(IRS Employer
Identification No.)
135 Duryea Road
,
Melville
,
New York
(Address of principal executive offices)
11747
(Zip Code)
Registrant’s telephone number, including area code: (
631
)
843-5500
(Former name or former address, if changed since last
report.)
Check the appropriate box
below if the
Form 8-K filing is intended to simultaneously satisfy
the filing obligation of
the registrant under any
of the following
provisions:
☐
Written communications pursuant
to Rule 425
under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to
Rule 14a-12 under
the Exchange Act (17
CFR 240.14a-12)
☐
Pre-commencement communications pursuant to
Rule 14d-2(b) under
the Exchange Act
(17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to
Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to
Section 12(b) of the
Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $.01 per share
HSIC
The
Nasdaq
Global Select Market
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company,
indicate by check mark if the registrant has
elected not to use the extended transition period
for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of
the Exchange Act.
☐
Item 7.01
Regulation FD Disclosure.
On November 16, 2026, Henry Schein, Inc. (the “Company”) issued a press
release announcing an update to the
Company’s presentation of certain non-GAAP financial measures. Beginning with its fourth-quarter 2026 financial
results, the Company will exclude from its non-GAAP financial results
acquisition-related remeasurement gains arising
when it obtains a controlling interest in a business in which it previously
held a non-controlling equity interest.
The
press release includes historical financial information reflecting this change
for fiscal years 2024 and 2025 and the first
nine months of 2026, together with related reconciliations.
The change does not affect the Company’s previously
reported consolidated GAAP results.
In connection with this voluntary change, the Company updated its
full-year 2026
non-GAAP diluted earnings per share guidance to $5.42 to $5.48 from
$5.50 to $5.56, solely to reflect the impact of
excluding acquisition-related remeasurement gains.
There are no other changes to the Company’s 2026 financial
guidance or underlying business outlook as a result of this change.
A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01 and the press release attached as Exhibit
99.1 are considered furnished to the
Securities and Exchange Commission and are not deemed filed for purposes
of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall it be
deemed incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference
in such filing.
Item 9.01.
Financial Statements and Exhibits
(d)
Exhibit 99.1 – Press Release dated November 16, 2026.
Exhibit 104 - Cover Page Interactive Data File (embedded within the
Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
HENRY SCHEIN, INC.
By:
/s/ Emmanuel Caprais
Emmanuel Caprais
Senior Vice President and
Chief Financial Officer
(Authorized Signatory and Principal
Financial and Accounting Officer)
November 16, 2026
exhibit991p1i1 exhibit991p1i0
-1-
more
FOR IMMEDIATE RELEASE
HENRY SCHEIN UPDATES PRESENTATION
OF NON-GAAP FINANCIAL MEASURES
●
Company will exclude acquisition-related remeasurement gains from non-GAAP financial results.
This change better reflects
underlying operating performance and improves comparability across reporting periods
●
FY2026 non-GAAP diluted EPS guidance updated to $5.42 to $5.48 solely to reflect the change
MELVILLE, N.Y.,
November 16, 2026 –
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-
based dental and medical practitioners, today announced an update to its presentation of certain non-GAAP financial measures.
Beginning with its fourth-quarter 2026 financial results, Henry Schein will exclude the gains resulting from the remeasurement to fair value of
previously held equity interests from its non-GAAP financial results. These gains arise when the Company acquires a controlling interest in an entity in
which it previously held a non-controlling equity interest. Management believes excluding these gains better reflects underlying operating performance
and improves comparability across reporting periods.
This voluntary change does not affect the Company’s reported GAAP financial results. To
provide investors with consistent and comparable
financial information, Henry Schein has recast its historical operating income by segment, non-GAAP diluted earnings per share, and Adjusted EBITDA
for 2024, 2025 and the first nine months of 2026 to reflect the updated presentation. The recast historical information is included in the tables
accompanying this release.
Updated 2026 Financial Guidance
As a result of the announced change in the Company’s presentation of non-GAAP financial measures, Henry Schein is updating its FY2026
non-GAAP diluted EPS guidance to $5.42 to $5.48, compared with its previously announced guidance of $5.50 to $5.56. The $0.08 reduction reflects the
full year 2026 impact from the exclusion of acquisition-related remeasurement gains recognized in the first quarter of 2026. There are no other changes to
the Company’s 2026 financial guidance or its underlying business outlook as a result of this change.
Updated Guidance
Previous Guidance
Non-GAAP diluted EPS
$5.42 - $5.48
$5.50 - $5.56
Total sales growth
4.5% - 5.5%
4.5% - 5.5%
Adjusted EBITDA growth
High-single-digits
High-single-digits
The Company intends to apply this treatment to acquisition-related remeasurement gains in its non-GAAP financial measures going forward.
Guidance is for current continuing operations and does not include the impact of restructuring expenses and related costs, amortization expense
of acquired intangible assets, the impairment of intangible assets, changes in contingent consideration, select implementation-related costs supporting
value creation initiatives, litigation settlements, and acquisition-related remeasurement gains as described in this release. This guidance also assumes that
foreign currency exchange rates remain generally consistent with current levels and no significant tariff refunds in the fourth quarter of 2026.
-2-
more
Historical Non-GAAP Financial Information
The tables accompanying this release provide recast operating income by segment, non-GAAP diluted EPS and Adjusted EBITDA for 2024,
2025 and the first nine months of 2026. The recast information reflects the exclusion of acquisition-related remeasurement gains from the Company’s
non-GAAP results and is being provided to facilitate comparison of financial performance across periods. The change has no impact on the Company’s
historical GAAP financial statements.
Adjustments to 2026 GAAP Net Income and Diluted EPS
The Company is providing guidance for 2026 diluted EPS and for 2026
Adjusted EBITDA on a non-GAAP basis, as noted above. The
Company is not providing a reconciliation of its 2026 non-GAAP diluted EPS guidance to its projected 2026 diluted EPS prepared on a GAAP basis, or
its 2026 Adjusted EBITDA guidance to net income prepared on a GAAP basis. This is because the Company is unable to provide without unreasonable
effort an estimate of restructuring expenses and related costs, including its ongoing value-creation initiatives, and the corresponding tax effect, which will
be included in the Company’s 2026 diluted EPS and net income, prepared on a GAAP basis. The inability to provide this reconciliation is due to the
uncertainty and inherent difficulty of predicting the occurrence, magnitude, financial impact and timing of related costs.
Management does not believe these items are representative of the Company’s underlying business performance. For the same reasons, the
Company is unable to address the probable significance of the unavailable information, which could be material to future results.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a products, services, and technology platforms company for health care customers. With approximately
25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than
300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology and Supply Chain solutions help
office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental
laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and
Henry Schein corporate brand products in our main distribution centers.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y.,
and has operations or
affiliates in 34 countries and territories. The Company's sales reached $13.2 billion in 2025, and have grown at a compound annual rate of approximately
11.0 percent since Henry Schein became a public company in 1995.
For more information, visit Henry Schein at www.henryschein.com.
Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information
In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary
remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations
and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of
future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual
results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or
implied by such forward-looking statements.
These statements include total sales growth, EPS and Adjusted EBITDA guidance and statements about our business expectations, and are
generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to
be,” “to make” or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that
may affect our business and future prospects, is contained in documents we file with the United States Securities and Exchange Commission, or SEC,
including our Annual Report on Form 10-K, and will be contained in subsequent periodic filings we make with the SEC. These documents identify in
detail important risk factors that could cause our actual performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited
to: our dependence on third parties for the manufacture and supply of our products and where we manufacture products, our dependence on third parties
for raw materials or purchased components; risks relating to the achievement of our strategic growth objectives, including anticipated results of
restructuring and value creation initiatives; risks related to the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in
January 2025; transitions in senior company leadership, (including, without limitation, our Chief Executive Officer, Chief Financial Officer, and other
executive officers); our ability to develop or acquire and maintain and protect new products (particularly technology and specialty products) and services
and utilize new technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions and joint
ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal,
-3-
more
regulatory, compliance, financial and human resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in our
governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related
to the sale of corporate brand products; risks related to activist investors; security risks associated with our information systems and technology products
and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive
(including, without limitation, competition from third-party online commerce sites) and consolidating market; political, economic, and regulatory
influences on the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs
for our products or other service issues with our third-party shippers, and increases in fuel and energy costs; changes in laws and policies governing
manufacturing, development and investment in territories and countries where we do business; general global and domestic macro-economic and political
conditions, including inflation, deflation, recession, unemployment (and corresponding increase in under-insured populations), consumer confidence,
sovereign debt levels, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies and changes to other economic
indicators;
failure to comply with existing and future regulatory requirements, including relating to health care; risks associated with the EU Medical
Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws
and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or
transmissions; changes in tax legislation, changes in tax rates and availability of certain tax deductions; risks related to product liability, intellectual
property and other claims; risks associated with customs policies or legislative import restrictions; risks associated with disease outbreaks, epidemics,
pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters; risks associated
with our global operations; the threat or outbreak of war (including, without limitation, geopolitical wars), terrorism or public unrest (including, without
limitation, the wars in Ukraine and Iran, the Israel-Gaza conflict and other unrest and threats in the Middle East and the possibility of a wider European
or global conflict); changes to laws and policies governing foreign trade, tariffs and sanctions or greater restrictions on imports and exports, including
changes to international trade agreements and the current imposition of (and the potential for additional) tariffs by the U.S. on numerous countries and
retaliatory tariffs; supply chain disruption; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our
dependence on our senior management, employee hiring and retention, increases in labor costs or health care costs, and our relationships with customers,
suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their
relative importance or priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly,
any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation
to update forward-looking statements except as required by law.
Included within the press release are non-GAAP financial measures that supplement the Company’s Consolidated Statements of Income
prepared under generally accepted accounting principles (GAAP). These non-GAAP financial measures adjust the Company’s actual results prepared
under GAAP to exclude certain items. In the schedule attached to the press release, the non-GAAP measures have been reconciled to and should be
considered together with the Consolidated Statements of Income. Comparisons of non-GAAP performance across periods should be made using
measures calculated on a consistent basis, including the recast historical measures accompanying this release. Management believes that non-GAAP
financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of
financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to
key metrics used by management in operating our business. The impact of certain items that are excluded include integration and restructuring costs,
acquisition-related remeasurement gains, amortization of acquisition-related assets, the insurance claim recovery associated with the cybersecurity
incident, changes in contingent consideration, costs associated with shareholder advisory matters and select value creation consulting costs, and litigation
settlements because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we
consummate and occur on an unpredictable basis. These non-GAAP financial measures are presented solely for informational and comparative purposes
and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.
CONTACTS:
Investors
Graham Stanley
Vice President, Investor Relations and Strategic Financial Project Officer
graham.stanley@henryschein.com
(631) 843-5500
Media
Tim Vassilakos
Vice President, Global Corporate Communications
timothy.vassilakos@henryschein.com
(516) 510-0926
-4-
more
Table A
Henry Schein, Inc.
Full Year 2024
and 2025, and First Nine Months of 2026
Impact of recasting remeasurement gains to diluted EPS attributable to Henry Schein, Inc.
(unaudited)
First
Second
Third
Fourth
First
Second
Third
YTD
Full Year
Quarter
Quarter
Quarter
Quarter
Full Year
Quarter
Quarter
Quarter
September
2024
2025
2025
2025
2025
2025
2026
2026
2026
2026
Diluted EPS Attributable to Henry Schein, Inc.
GAAP EPS As Reported
$3.05
$0.88
$0.70
$0.84
$0.85
$3.27
$0.92
$0.82
$1.06
$2.80
Non-GAAP EPS Adjustments as Reported
1.68
0.26
0.40
0.54
0.50
1.70
0.39
0.45
0.50
1.34
Non-GAAP EPS As Reported
4.74
1.15
1.10
1.38
1.34
4.97
1.32
1.27
1.56
4.14
Impact of Recasting of Remeasurement Gains
(0.16)
-
(0.03)
(0.23)
(0.05)
(0.32)
(0.08)
-
-
(0.08)
Non-GAAP EPS As Recast
$4.58
$1.15
$1.07
$1.15
$1.29
$4.65
$1.24
$1.27
$1.56
$4.06
Note: Amounts may not sum, and certain amounts may differ from amounts previously presented, due to rounding and the use of weighted-average share counts, as applicable.
-5-
more
Table B
Henry Schein, Inc.
Full Year 2024
and 2025, and First Nine Months of 2026
Impact of recasting remeasurement gains to Operating Income
(in millions)
(unaudited)
First
Second
Third
Fourth
First
Second
Third
YTD
Full Year
Quarter
Quarter
Quarter
Quarter
Full Year
Quarter
Quarter
Quarter
September
2024
2025
2025
2025
2025
2025
2026
2026
2026
2026
Operating Income As Reported
Global Distribution and Value
-Added Services
$696
$167
$159
$178
$176
$680
$183
$181
$221
$585
Global Specialty Products
178
56
52
71
63
242
58
62
56
176
Global Technology
152
42
45
46
47
180
46
49
53
148
Total Segment Operating Income
1,026
265
256
295
286
1,102
287
292
330
909
Corporate
(77)
(35)
(31)
(33)
(31)
(130)
(34)
(42)
(51)
(127)
Adjustments
(328)
(55)
(74)
(98)
(92)
(319)
(71)
(79)
(86)
(236)
Total Operating Income
$621
$175
$151
$164
$163
$653
$182
$171
$193
$546
Remeasurement Gain Adjustments
Global Distribution and Value
-Added Services
$(19)
$-
$(4)
$-
$(5)
$(9)
$-
$-
$-
$-
Global Specialty Products
-
-
-
(28)
(1)
(29)
(11)
-
-
(11)
Total Remeasurement Gains
$(19)
$-
$(4)
$(28)
$(6)
$(38)
$(11)
$-
$-
$(11)
Operating Income As Recast
Global Distribution and Value
-Added Services
$677
$167
$155
$178
$171
$671
$183
$181
$221
$585
Global Specialty Products
178
56
52
43
62
213
47
62
56
165
Global Technology
152
42
45
46
47
180
46
49
53
148
Total Segment Operating Income as Recast
1,007
265
252
267
280
1,064
276
292
330
898
Corporate
(77)
(35)
(31)
(33)
(31)
(130)
(34)
(42)
(51)
(127)
Adjustments as Recast
(309)
(55)
(70)
(70)
(86)
(281)
(60)
(79)
(86)
(225)
Total Operating Income
$621
$175
$151
$164
$163
$653
$182
$171
$193
$546
-6-
###
Table C
Henry Schein, Inc.
Full Year 2024
and 2025, and First Nine Months of 2026
Impact of recasting remeasurement gains to Adjusted EBITDA
(in millions)
(unaudited)
First
Second
Third
Fourth
First
Second
Third
YTD
Full Year
Quarter
Quarter
Quarter
Quarter
Full Year
Quarter
Quarter
Quarter
September
2024
2025
2025
2025
2025
2025
2026
2026
2026
2026
EBITDA
GAAP Net income as Reported
$398
$113
$94
$109
$103
$419
$112
$102
$126
$340
Definitional, Non-GAAP, and
Other Adjustments as
Reported
663
146
162
186
188
682
177
186
195
558
Non-GAAP Adjusted EBITDA as Reported
1,061
259
256
295
291
1,101
289
288
321
898
Remeasurement Gains
(19)
-
(4)
(28)
(6)
(38)
(11)
-
-
(11)
Non-GAAP Adjusted EBITDA as Recast
$1,042
$259
$252
$267
$285
$1,063
$278
$288
$321
$887

Filing Exhibits & Attachments

4 documents

Keep reading